Claude Drug Development: What Six Partner Labs Achieved

Most conversations about AI in medicine stop at molecule design. Anthropic's new update on drug development with Claude goes much further. On October 27, 2026, the company published early results from deep research partnerships with six organizations developing new medicines, and the numbers span almost every stage of the pipeline, from finding drug candidates to drafting the paperwork needed for clinical trials.

• Six partners: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group
• Antibody design at scale: Claude generated roughly 35,000 antibody designs in about a month for a food allergy program at Divergence Labs
• Paperwork relief: at Enveda, Claude-assisted document review cut human review time by 89%, from over 25 hours to under three
• In-house research: Anthropic acquired Mithril Medicine and hopes a muscular dystrophy candidate could enter human trials as soon as late 2028

How Is Claude Being Used in Drug Development?

Anthropic's core argument is that drug development has no single bottleneck. Target selection, molecule design, manufacturing records, regulatory filings and trial planning all slow things down, so the company embedded Claude in real programs across those stages. Each partner shared a technical report, and the highlights are striking.

Designing better molecules

Generate Biomedicines is working to adapt CAR T-cell therapy, a blood cancer treatment, for solid tumors. Six of its scientists used Claude Code to propose new versions of one genetic component. According to Anthropic, one design was about 70% shorter than the standard version and, in lab tests, let immune cells make roughly 10 times as many cancer-spotting receptors while killing tumor cells more efficiently.

At Divergence Labs, Claude turned the team's goals into a design plan for a two-armed antibody aimed at food allergies, then largely autonomously produced the 35,000 candidates. Early tests found three designs that bind the allergy molecule IgE and 20 that could dislodge it from immune cells, three of which appeared to outperform the standard medication.

Optimizing leads in the lab

BigHat Biosciences connected Claude to its lab data system, and its lab made and tested about 1,010 variants in roughly 10 weeks. The best versions bound more than 10 times more tightly than the originals, and one stayed in solution at temperatures 18°C higher. Notably, Claude and an Anthropic researcher also questioned the standard stability metrics mid-project and proposed better ones, which held up in testing.

Can AI Speed Up Clinical Trial Paperwork?

This may be the most immediately practical result. Enveda's manufacturing chemists spent up to 75% of their time on documentation. Across 1,061 pages of records, Claude caught all 11 issues human reviewers had found and flagged seven they had missed. It also drafted a key regulatory document in four hours, a job that took about three months by hand.

Bristol Myers Squibb is using Claude to assess clinical trial plans for an early-stage drug and estimate the likelihood of success, with plans to expand the work in 2027. The Column Group is founding a new company, Pleiades, built to run more drug programs with a small team using Claude.

What Comes Next for AI-Assisted Medicine

Anthropic is clear that this research is still early and mostly preclinical, meaning the medicines have not yet been tested in people. The most personal example is Mithril Medicine, a one-person company whose founder used Claude to coordinate work with 11 external labs and took a muscular dystrophy treatment from idea to promising mouse results in under 18 months. Anthropic has acquired the company and plans to scale the work.

For researchers, the takeaway is that the gains are spread across the whole workflow rather than concentrated in one flashy step. That pattern echoes the access efforts behind Anthropic's life sciences verification program, and it is a reminder of how broad AI's impact on medicine could become. For more model and research news, see our AI coverage.

Sources: Anthropic: Early progress on accelerating drug development with Claude — October 27, 2026; Anthropic Newsroom — accessed October 28, 2026.